-
公开(公告)号：EP0651809B1
公开(公告)日：2001-12-05
申请号：EP91912876.9
申请日：1991-06-03
发明人： BOULTON, Teri, G. , COBB, Melanie, H. , YANCOPOULOS, George, D. , NYE, Steven , PANAYOTATOS, Nikos
CPC分类号： G01N33/5041 , C12N9/12 , C12Q1/485 , G01N33/5008 , G01N33/573 , G01N2333/9121 , G01N2500/00
摘要： The present invention relates to a newly identified family of protein serine/threonine kinases which phosphorylate microtubule-associated protein 2 (MAP2). It is based, in part, on the cloning and characterization of novel MAP2 kinases designated extracellular signal-regulated kinase 1, 2, and 3 (ERK1, ERK2, ERK3) which are expressed in the central nervous system, and on the identification of another ERK family member, ERK4, with antisera. The present invention provides fore recombinant nucleic acid molecules and proteins representing members of the MAP2 kinase family, and also for microorganisms, transgenic animals, and cell lines comprising recombinant MAP2 kinase molecules. In additional embodiments of the invention, the present invention provides for methods for assaying cellular factor activity, including, but not limited to, nerve growth factor activity, in which the activation of MAP2 kinase serves as an indicator of cellular factor activity. These methods may be extremely useful in screening compounds for the presence of a desired cellular factor activity. In specific embodiments, compounds which may be useful in the treatment of Alzheimer's disease , peripheral neuropathies, and diabetes may be identified using the methods of the invention.
-
公开(公告)号：EP0651809A1
公开(公告)日：1995-05-10
申请号：EP91912876.0
申请日：1991-06-03
发明人： BOULTON, Teri, G. , COBB, Melanie, H. , YANCOPOULOS, George, D. , NYE, Steven , PANAYOTATOS, Nikos
CPC分类号： G01N33/5041 , C12N9/12 , C12Q1/485 , G01N33/5008 , G01N33/573 , G01N2333/9121 , G01N2500/00
摘要： The present invention relates to a newly identified family of protein serine/threonine kinases which phosphorylate microtubule-associated protein 2 (MAP2). It is based, in part, on the cloning and characterization of novel MAP2 kinases designated extracellular signal-regulated kinase 1, 2, and 3 (ERK1, ERK2, ERK3) which are expressed in the central nervous system, and on the identification of another ERK family member, ERK4, with antisera. The present invention provides fore recombinant nucleic acid molecules and proteins representing members of the MAP2 kinase family, and also for microorganisms, transgenic animals, and cell lines comprising recombinant MAP2 kinase molecules. In additional embodiments of the invention, the present invention provides for methods for assaying cellular factor activity, including, but not limited to, nerve growth factor activity, in which the activation of MAP2 kinase serves as an indicator of cellular factor activity. These methods may be extremely useful in screening compounds for the presence of a desired cellular factor activity. In specific embodiments, compounds which may be useful in the treatment of Alzheimer's disease , peripheral neuropathies, and diabetes may be identified using the methods of the invention.
-
3.发明授权RODENT CAPABLE OF PRODUCING HYBRID ANTIBODIES CONTAINING HUMAN VARIABLE REGIONS AND RODENT CONSTANT REGIONS 有权ON OFF的人可变区和啮齿动物的常数杂种抗体制造鼠类
公开(公告)号：EP2787075B1
公开(公告)日：2016-11-30
申请号：EP14172420.3
申请日：2002-02-15
发明人： MURPHY, Andrew J. , YANCOPOULOS, George, D. , ECONOMIDES, Aris , KAROW, Margaret , MACDONALD, Lynn , STEVENS, Sean , VALENZUELA, David
IPC分类号： C12N15/00 , C12N15/09 , C12N15/63 , C12N15/74 , C12N5/00 , C12N5/02 , C12N5/16 , C12P21/06 , C12P21/04
CPC分类号： C12P21/00 , A01K67/0275 , A01K67/0278 , A01K2207/15 , A01K2217/05 , A01K2227/105 , A01K2267/01 , C07K16/00 , C07K16/28 , C07K16/462 , C07K2317/10 , C07K2317/21 , C07K2317/24 , C07K2317/51 , C07K2317/515 , C07K2317/56 , C12N15/67 , C12N15/85 , C12N15/8509 , C12N15/902 , C12N15/907 , C12N2800/204
-
公开(公告)号：EP1360287B1
公开(公告)日：2012-09-12
申请号：EP02709544.7
申请日：2002-02-15
CPC分类号： C12P21/00 , A01K67/0275 , A01K67/0278 , A01K2207/15 , A01K2217/05 , A01K2227/105 , A01K2267/01 , C07K16/00 , C07K16/28 , C07K16/462 , C07K2317/10 , C07K2317/21 , C07K2317/24 , C07K2317/51 , C07K2317/515 , C07K2317/56 , C12N15/67 , C12N15/85 , C12N15/8509 , C12N15/902 , C12N15/907 , C12N2800/204
摘要： A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.
-
公开(公告)号：EP1563298A2
公开(公告)日：2005-08-17
申请号：EP03742008.0
申请日：2003-06-17
CPC分类号： C40B30/04 , C07K14/685 , C07K14/705 , C07K14/70535 , C07K16/44 , C07K2317/622 , C07K2319/00 , C07K2319/30 , G01N33/6845 , G01N33/6857
摘要： Methods for identifying a compound capable of modulating activity of a target active domain, by generating a first fusion protein having an anchor component and a variable component, generating a second fusion protein having a docking domain and an active domain, wherein the anchor component and the docking domain are binding partners, then contacting the fusion proteins under conditions in which the anchor component and the docking domain bind, and determining the activity of the target domain.
-
公开(公告)号：EP0866860B1
公开(公告)日：2004-03-31
申请号：EP96945068.3
申请日：1996-12-13
IPC分类号： C12N15/12 , C12N15/16 , C12N15/70 , C12N15/81 , C12N15/85 , C12N5/10 , C12N1/19 , C12N1/21 , C12Q1/68 , C12P21/02 , C07K14/575 , C07K16/26 , A61K38/22 , A61K48/00 , G01N33/53
CPC分类号： C07K14/78 , A61K38/00 , A61K48/00 , C07K14/70567 , C07K14/70571 , C07K14/811 , C07K16/38
摘要： The present invention provides for a gene, designated as musk , that encodes a novel tyrosine kinase receptor expressed in high levels in denervated muscle. The invention also provides for an isolated polypeptide which activates MuSK receptor. The invention further provides for a polypeptide which is functionally equivalent to the MuSK activating polypeptide. The invention also provides assay systems that may be used to detect and/or measure ligands that bind the musk gene product. The present invention also provides for diagnostic and therapeutic methods based on molecules that activate MuSK.
-
公开(公告)号：EP1231934B1
公开(公告)日：2004-03-24
申请号：EP00980561.5
申请日：2000-11-17
CPC分类号： G01N33/5061 , A61K38/30 , G01N33/5008 , G01N33/5041 , G01N33/5044
摘要： The present invention provides a method for inhibiting atrophy or causing hypertrophy in muscle cells. It further provides a method for inhibiting skeletal muscle atrophy or causing skeletal muscle hypertrophy in vertebrate animals. It also provides a method of identifying agents that may be method for inhibiting atrophy or causing hypertrophy in muscle cells.
-
公开(公告)号：EP0915974B1
公开(公告)日：2004-03-17
申请号：EP97937086.3
申请日：1997-08-01
IPC分类号： C12N15/12 , C07K14/515 , C07K14/71 , C07K16/22 , C12N15/62 , C07K19/00 , A61K38/17 , A61K38/18 , A61K39/395 , A61K49/00 , A61K51/08
CPC分类号： C12N15/8509 , A01K2207/15 , A01K2217/00 , A01K2217/05 , A01K2217/075 , A01K2227/105 , A01K2227/30 , A01K2267/01 , A01K2267/03 , A01K2267/0331 , A01K2267/0375 , A01K2267/0381 , A61K38/00 , C07K14/515 , C07K14/71 , C07K2319/00 , C07K2319/02
摘要： The present invention provides for a modified TIE-2 ligand which has been altered by addition, deletion or substitution of one or more amino acids, or by way of tagging, with for example, the Fc portion of human IgG-1, but which retains its ability to bind the TIE-2 receptor. The invention further provides for a modified TIE-2 ligand which is a chimeric TIE-2 ligand comprising at least a portion of a first TIE-2 ligand and a portion of a second TIE-2 ligand which is different from the first. In a specific embodiment, the invention further provides for a chimeric TIE ligand comprising at least a portion of TIE-2 Ligand-1 and a portion of TIE-2 Ligand-2. In addition the present invention provides for isolated nucleic acid molecule encoding the modified TIE-2 ligands described. The invention also provides for therapeutic compositions as well as a method of blocking blood vessel growth, a method of promoting neovascularization, a method of promoting the growth or differentiation of a cell expressing the TIE receptor, a method of blocking the growth or differentiation of a cell expressing the TIE receptor and a method of attenuating or preventing tumor growth in a human.
-
9.发明公开METHOD OF USING A VARIANT OF VEGF RECEPTOR TO TREAT PSORIASIS AND TO ENHANCE WOUND HEALING 审中-公开使用方法VEGF受体的一个变种牛皮癣的治疗和促进伤口愈合的
公开(公告)号：EP1363677A1
公开(公告)日：2003-11-26
申请号：EP02706033.4
申请日：2002-01-28
CPC分类号： C07K14/71 , A61K38/00 , C07K2319/00
摘要： Modified chimeric polypeptides with improved pharmacokinetics are disclosed. Specifically, modified chimeric Flt1 receptor polypeptides that have been modified in such a way as to improve their pharmacokinetic profile are disclosed. Also disclosed are methods of making and using the modified polypeptides including but not limited to using the modified polypeptides to decrease or inhibit plasma leakage and/or vascular permeability in a mammal. Also disclosed are methods of treating diseases in which plasma leakage and/or vascular permeability occurs, for example, inflammatory skin diseases.
-
公开(公告)号：EP0939809B1
公开(公告)日：2003-03-26
申请号：EP97930162.9
申请日：1997-06-19
IPC分类号： C12N15/12 , C07K14/17 , A61K38/18 , C07K14/745 , C07K16/22
CPC分类号： C07K14/71 , A01K2207/15 , A01K2217/00 , A01K2217/05 , A01K2217/075 , A01K2227/10 , A01K2227/105 , A01K2267/01 , A01K2267/03 , A61K38/00 , C07K14/515 , C07K2319/00 , C07K2319/02 , C12N15/8509
摘要： The present invention provides for an isolated nucleic acid molecule encoding a member of the TIE ligand family. The present invention also provides for an isolated nucleic acid molecule encoding TIE ligand-3 or TIE ligand-4. In addition, the invention provides for a receptor body which specifically binds TIE ligand-3 or TIE ligand-4. The invention also provides an antibody which specifically binds TIE ligand-3 or TIE ligand-4. The invention further provides for an antagonist of TIE. The invention also provides for therapeutic compositions as well as a method of blocking blood vessel growth, a method of promoting neovascularization, a method of promoting the growth or differentiation of a cell expressing the TIE receptor, a method of blocking the growth or differentiation of a cell expressing the TIE receptor and a method of attenuating or preventing tumor growth in a human.
-
-
-
-
-
-
-
-
-
搜索结果
73 条记录 (耗时 0.04 秒)
